发明名称 |
Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agent |
摘要 |
The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an NAE inhibitor or a pharmaceutically acceptable salt thereof, such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine. Also disclosed are medicaments for use in the treatment of cancer. |
申请公布号 |
US8980850(B2) |
申请公布日期 |
2015.03.17 |
申请号 |
US201213667641 |
申请日期 |
2012.11.02 |
申请人 |
Millennium Pharmaceuticals, Inc. |
发明人 |
Smith Peter G. |
分类号 |
A01N43/04;A61K31/70;A61K31/706;A61K45/06;A61K31/519 |
主分类号 |
A01N43/04 |
代理机构 |
Finnegan, Henderson, Farabow, Garrett & Dunner |
代理人 |
Finnegan, Henderson, Farabow, Garrett & Dunner |
主权项 |
1. A method of treating cancer comprising, administering to a patient in need of such treatment a therapeutically effective total amount of
an NAE inhibitor or a pharmaceutically acceptable salt thereof, and a hypomethylating agent or a pharmaceutically acceptable salt thereof. |
地址 |
Cambridge MA US |